Rohan Palekar
Chief Executive Officer en 89BIO, INC. .
Fortuna: 6 M $ al 29/02/2024
Perfil
Currently, Rohan Palekar occupies the position of Chairman at Aim High For High School, Chief Executive Officer & Director at 89bio, Inc. and Chief Executive Officer for Xenerex Biosciences.
Mr. Palekar is also on the board of Neurogene, Inc.
In the past he occupied the position of President & Chief Executive Officer at Avanir Pharmaceuticals, Inc., Chief Commercial Officer of Medivation LLC (California) and Vice President-Dermatology Sales & Marketing at Centocor, Inc.
Mr. Palekar received a graduate degree and an undergraduate degree from the University of Mumbai and an MBA from Tuck School of Business at Dartmouth.
Participaciones conocidas en empresas públicas
Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
---|---|---|---|---|
89BIO INC
0.54% | 26/02/2024 | 486 889 ( 0.54% ) | 6 M $ | 29/02/2024 |
Cargos activos de Rohan Palekar
Empresas | Cargo | Inicio |
---|---|---|
89BIO, INC. | Chief Executive Officer | 01/06/2018 |
Xenerex Biosciences
Xenerex Biosciences Miscellaneous Commercial ServicesCommercial Services Xenerex Biosciences engages in developing and commercializing human antibody products to target antigens. The company was founded by John David Hansen and Wolfgang W. Scholz and is headquartered in Aliso Viejo, CA. | Chief Executive Officer | - |
Aim High For High School | Chairman | - |
Antiguos cargos conocidos de Rohan Palekar.
Empresas | Cargo | Fin |
---|---|---|
AVANIR PHARMACEUTICALS INC | Chief Executive Officer | 31/12/2017 |
MEDIVATION INC | Corporate Officer/Principal | 09/09/2011 |
Centocor, Inc.
Centocor, Inc. Medical SpecialtiesHealth Technology Centocor, Inc. manufactures healthcare products. Its products include avakine & reopro. The company was founded in 1979 by Hubert J. P. Schoemaker & Michael A. Wall and is headquartered in Horsham, PA. | Sales & Marketing | 01/12/2007 |
NEUROGENE INC. | Director/Board Member | - |
Formación de Rohan Palekar.
University of Mumbai | Graduate Degree |
Tuck School of Business at Dartmouth | Masters Business Admin |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
89BIO, INC. | Health Technology |
Empresas privadas | 6 |
---|---|
Centocor, Inc.
Centocor, Inc. Medical SpecialtiesHealth Technology Centocor, Inc. manufactures healthcare products. Its products include avakine & reopro. The company was founded in 1979 by Hubert J. P. Schoemaker & Michael A. Wall and is headquartered in Horsham, PA. | Health Technology |
Avanir Pharmaceuticals, Inc.
Avanir Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Avanir Pharmaceuticals, Inc. engages in the development of therapeutic products for the treatment of nervous system disorder. The company was founded on August 31, 1988 and headquartered in Aliso Viejo, CA. | Health Technology |
Medivation LLC (California)
Medivation LLC (California) Pharmaceuticals: MajorHealth Technology Medivation LLC engages in the development and commercialization of novel therapies to treat serious diseases for which there are limited treatment options. The company was founded by Clarence Patrick Machado and David T. Hung in 2004 and is headquartered in San Francisco, CA. | Health Technology |
Xenerex Biosciences
Xenerex Biosciences Miscellaneous Commercial ServicesCommercial Services Xenerex Biosciences engages in developing and commercializing human antibody products to target antigens. The company was founded by John David Hansen and Wolfgang W. Scholz and is headquartered in Aliso Viejo, CA. | Commercial Services |
Neoleukin Therapeutics, Inc.
Neoleukin Therapeutics, Inc. BiotechnologyHealth Technology Neoleukin Therapeutics, Inc. operates as a biopharmaceutical company, which computational methods to design de novo protein therapeutics. The firm address significant medical needs in oncology, inflammation, and autoimmunity. Its lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. The company was founded by Daniel-Adriano Silva, Carl Walkey, and Umut Ulge in December 2003 and is headquartered in Seattle, WA. | Health Technology |
Aim High For High School |